A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Conditions:   AML;   MDS Intervention:   Drug: SHR-1702 Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2020 Category: Research Source Type: clinical trials

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Conditions:   Myelodysplastic Syndromes;   Cytopenia Intervention:   Drug: KER-050 Sponsor:   Keros Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2020 Category: Research Source Type: clinical trials

A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome
Condition:   Higher Risk Myelodysplastic Syndromes Interventions:   Drug: ALX148;   Drug: Azacitidine Sponsor:   ALX Oncology Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2020 Category: Research Source Type: clinical trials

Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from a single-arm, open-label Phase 1b trial of magrolimab, an investigational anti-CD47 monoclonal antibody, in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 29, 2020 Category: Pharmaceuticals Source Type: clinical trials

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, in Relapse;   Myelodysplastic Syndromes Intervention:   Drug: CB-5339 Sponsor:   Cleave Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Condition:   Myelodysplastic Syndrome (MDS) Interventions:   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Placebo Sponsor:   AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.
Condition:   Myelodysplastic Syndromes Intervention:   Other: Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression Sponsor:   University Hospital, Grenoble Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2020 Category: Research Source Type: clinical trials

Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Condition:   Myelodysplastic Syndrome (MDS) Interventions:   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Placebo Sponsor:   AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2020 Category: Research Source Type: clinical trials

Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.
Condition:   Myelodysplastic Syndromes Intervention:   Other: Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression Sponsor:   University Hospital, Grenoble Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2020 Category: Research Source Type: clinical trials